ADROPIN--POTENTIAL LINK IN CARDIOVASCULAR PROTECTION FOR OBESE MALE TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH LIRAGLUTIDE/ADROPIN--POTENCIJALNI CIMBENIK KARDIOVASKULARNE SIGURNOSTI U MUSKARACA OBOLJELIH OD SECERNE BOLESTI TIP 2 LIJECENIH LIRAGLUTIDOM

The aim of this study was to determine plasma adropin concentration and parameters of insulin resistance in obese male type 2 diabetes mellitus (T2DM) patients before and after 3-month liraglutide treatment. In this interventional study, we enrolled 15 obese male T2DM patients with body mass index (BMI) >35 kg/[m.sup.2], uncontrolled disease and Hb[A.sub.1c] >7.5%, having previously taken taking two oral antidiabetic drugs. We modified their therapy to metformin and liraglutide for the next three months. After three months of liraglutide treatment, we observed significant decrease in body weight (from 111.5[+ or -]18.7 kg to 109.2[+ or -]17.5 kg, p=0.016) and BMI (from 40.9[+ or -]7.3 to 40.1[+ or -]7.0 kg/[m.sup.2], p=0.021). Plasma adropin concentration increased significantly (p=0.003) compared with baseline. Fasting plasma insulin level decreased from 17.79[+ or -]6.53 to 13.38[+ or -]3.51 mU/L (p=0.002), fasting plasma glucose level decreased from 8.66[+ or -]3.07 to 7.41[+ or -]2.21 mmol/L (p=0.004) and Hb[A.sub.1c] decreased from 7.98[+ or -]0.70% to 7.26[+ or -]0.36% (p=0.003). Insulin resistance presented as HOMA-IR decreased significantly from 7.30+5.19 to 4.52[+ or -]2.61 (p=0.002). Systolic blood pressure, lipid status, liver and kidney function improved, but not reaching statistical significance. Treating obese male T2DM patients with liraglutide resulted in a significantly higher plasma adropin concentration, significant weight loss and improved parameters of insulin resistance, i.e. decreased fasting plasma insulin, plasma glucose levels and HOMA-IR. Key words: Diabetes mellitus type 2; Insulin resistance; Obesity; Adropin; Liraglutide; Endothelial cell dysfunction Cilj je bio usporediti plazmatske vrijednosti adropina i parametre inzulinske rezistencije kod pretilih muškaraca koji boluju od šecerne bolesti tip 2 (SBT2) prije i nakon 3 mjeseca primjene liraglutida. U ovoj intervencijskoj studiji sudjelovalo je 15 pretilih muškaraca koji boluju od SBT2 s indeksom tjelesne mase (ITM) >35 kg/[m.sup.2], loše reguliranom bolešcu i Hb[A.sub.1c] >7,5%. Ispitanici su prethodno u terapiji imali dva peroralna antidijabeticna lijeka. Nakon ukljucenja u studiju terapija im je modificirana na metformin i liraglutid tijekom tri mjeseca. Nakon primjene liraglutida kod ispitanika je zamijeceno smanjenje tjelesne mase (sa 111,5[+ or -]18,7 na 109,2[+ or -]17,5 kg, p=0,016) i ITM (s 40,9[+ or -]7,3 na 40,1[+ or -]7,0 kg/[m.sup.2], p=0,021), dok su plazmatske